Despite the tough public financing environment, venture capitalists are more than willing to dole out the dollars to support good ideas, good science and good management. (BioWorld Financial Watch)

A drug's blow-up in Phase III trials is hardly easy to take in stride, but Biogen Inc. came out of its failure last week seeming not much the worse for wear in the eyes of Wall Street, even if nobody at the company was popping champagne corks. (BioWorld Financial Watch)